Neurovascular de-coupling underlies dual-task cost across cognitive abilities

IF 6.8 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Pub Date : 2025-10-07 DOI:10.1002/trc2.70156

Laura K. Fitzgibbon-Collins, Sarah Best, Mamiko Noguchi, Corey Guest, Michael Borrie, J. Kevin Shoemaker, Jaspreet Bhangu

{"title":"Neurovascular de-coupling underlies dual-task cost across cognitive abilities","authors":"Laura K. Fitzgibbon-Collins, Sarah Best, Mamiko Noguchi, Corey Guest, Michael Borrie, J. Kevin Shoemaker, Jaspreet Bhangu","doi":"10.1002/trc2.70156","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>We tested the hypothesis that increased middle cerebral artery velocity (MCA velocity) during complex motor (overground walking) and cognitive tasks (e.g., dual task) is associated with cognitive performance in older adults with varying levels of cognitive ability.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>Fifty-six participants (19 females, 75 ± 7 years old) completed a seated single task that assessed working memory performance; a walking single task, assessing overground walking gait speed; and a dual task, combining both. Continuous MCA velocity was collected, and participants completed a Montreal Cognitive Assessment (MoCA).</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Higher MCA velocity was associated with faster gait speed, better working memory performance, and greater MoCA scores (all <i>p</i> < 0.05). Participants with lower MoCA scores had lower MCA velocity (<i>p</i> = 0.052), slower gait speed (<i>p</i> = 0.035), and lower working memory performance (<i>p</i> = 0.016) than people with higher MoCA scores. The hyperemic response of MCA velocity from single task walking to the dual task with increased cognitive load significantly contributed to MoCA scores (<i>p</i> = 0.017).</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>The functional response of cerebral blood flow with these tests suggests vascular properties may be considered a biomarker indicative of subclinical cognitive function during walking tasks.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Mobile devices simultaneously assessed neurovascular coupling and dual-task cost.</li>\n \n <li>Middle cerebral artery velocity (MCA velocity) is negatively associated with dual-task cost.</li>\n \n <li>MCA velocity is associated with gait speed, working memory, and Montreal Cognitive Assessment scores.</li>\n \n <li>MCA velocity decreased from controls to mild cognitive impairment to dementia.</li>\n \n <li>Novel methodological approach to utilize MCA velocity during overground walking, single-tasks, and dual-tasks.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 4","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70156","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.70156","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

We tested the hypothesis that increased middle cerebral artery velocity (MCA velocity) during complex motor (overground walking) and cognitive tasks (e.g., dual task) is associated with cognitive performance in older adults with varying levels of cognitive ability.

METHODS

Fifty-six participants (19 females, 75 ± 7 years old) completed a seated single task that assessed working memory performance; a walking single task, assessing overground walking gait speed; and a dual task, combining both. Continuous MCA velocity was collected, and participants completed a Montreal Cognitive Assessment (MoCA).

RESULTS

Higher MCA velocity was associated with faster gait speed, better working memory performance, and greater MoCA scores (all p < 0.05). Participants with lower MoCA scores had lower MCA velocity (p = 0.052), slower gait speed (p = 0.035), and lower working memory performance (p = 0.016) than people with higher MoCA scores. The hyperemic response of MCA velocity from single task walking to the dual task with increased cognitive load significantly contributed to MoCA scores (p = 0.017).

DISCUSSION

The functional response of cerebral blood flow with these tests suggests vascular properties may be considered a biomarker indicative of subclinical cognitive function during walking tasks.

Highlights

Mobile devices simultaneously assessed neurovascular coupling and dual-task cost.
Middle cerebral artery velocity (MCA velocity) is negatively associated with dual-task cost.
MCA velocity is associated with gait speed, working memory, and Montreal Cognitive Assessment scores.
MCA velocity decreased from controls to mild cognitive impairment to dementia.
Novel methodological approach to utilize MCA velocity during overground walking, single-tasks, and dual-tasks.

Abstract Image

查看原文本刊更多论文

神经血管解耦是跨认知能力的双重任务成本的基础

我们检验了在复杂运动（地上行走）和认知任务（如双重任务）中大脑中动脉速度（MCA速度）的增加与认知能力水平不同的老年人的认知表现有关的假设。方法56名参与者（19名女性，75±7岁）完成一项评估工作记忆表现的坐姿单任务；一项步行单任务，评估地上行走的步态速度；这是一项双重任务，将两者结合起来。收集连续的MCA速度，并完成蒙特利尔认知评估（MoCA）。结果较高的MCA速度与更快的步态速度、更好的工作记忆表现和更高的MoCA评分相关（均p <； 0.05）。与MoCA得分较高的人相比，MoCA得分较低的参与者MCA速度较低（p = 0.052），步态速度较慢（p = 0.035），工作记忆表现较差（p = 0.016）。单任务行走到认知负荷增加的双任务时，MCA速度的充血反应对MoCA评分有显著影响（p = 0.017）。脑血流的功能反应与这些测试表明，血管特性可能被认为是行走任务中亚临床认知功能的生物标志物。移动设备同时评估神经血管耦合和双任务成本。大脑中动脉流速与双任务成本呈负相关。MCA速度与步态速度、工作记忆和蒙特利尔认知评估得分有关。从对照组到轻度认知障碍再到痴呆，MCA速度下降。在地面行走、单任务和双任务中利用MCA速度的新方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Medicine-Psychiatry and Mental Health

CiteScore

10.10

自引率

2.10%

发文量

134

审稿时长

10 weeks

期刊介绍： Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.